Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study

Ina Mathilde Kjær*, Dorte Aalund Olsen, Ivan Brandslund, Troels Bechmann, Erik Hugger Jakobsen, Søren Bie Bogh, Jonna Skov Madsen

*Kontaktforfatter for dette arbejde

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

14 Downloads (Pure)

Abstrakt

The epidermal growth factor receptor (EGFR) and its ligands are involved in cancer pathogenesis and they might serve as circulating biomarkers. The current study aims to investigate if abnormal pre-treatment serum levels of EGFR and EGFR ligands are present in women with early-stage breast cancer and if up- or downregulation of EGFR and EGFR ligands occur in defined patient subgroups. Pre-treatment serum samples were obtained from 311 women with newly diagnosed early-stage breast cancer and from 419 healthy women and analysed for EGFR and the ligands: Epidermal growth factor (EGF), heparin-binding epidermal growth factor (HBEGF), betacellulin (BTC), amphiregulin (AREG), and transforming growth factor α (TGF-α). Previously, age-dependent 95% reference intervals for EGFR and the EGFR ligands have been established based on the healthy women population. S-EGFR, S-EGF, S-HBEGF, S-AREG, and S-TGFα were all significantly different in women with breast cancer compared to healthy women (p < 0.05). Elevated S-EGFR, according to the reference intervals, was present in 11.3% of breast cancer patients, whereas decreased S-EGF was found in 11.6%. Elevated S-EGFR was associated with estrogen receptor positivity of tumor (ER+) and a subgroup of ER + breast cancer patients showed markedly elevated S-EGFR (>120 ng/mL).

OriginalsprogEngelsk
Artikelnummer6714
TidsskriftScientific Reports
Vol/bind10
Antal sider9
ISSN2045-2322
DOI
StatusUdgivet - apr. 2020

Fingeraftryk Dyk ned i forskningsemnerne om 'Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study'. Sammen danner de et unikt fingeraftryk.

  • Citationsformater